Comparison of escitalopram vs. citalopram and venlafaxine in the treatment of major depression in Spain: clinical and economic consequences.
Sicras-Mainar
Antoni
A
Badalona Serveis Assistencials, SA, Department of Planning, Badalona, Spain. asicras@bsa.cat
Navarro-Artieda
Ruth
R
Blanca-Tamayo
Milagrosa
M
Gimeno-de la Fuente
Victoria
V
Salvatella-Pasant
Jordi
J
D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000191:economics; D015283:Citalopram / Q000008:administration & dosage* / Q000191:economics*; D003362:Cost-Benefit Analysis; D003511:Cyclohexanols / Q000008:administration & dosage* / Q000191:economics*; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000191:economics*; D004338:Drug Combinations; D016527:Drug Costs; D005260:Female; D017048:Health Care Costs; D006295:Health Resources / Q000191:economics / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D012189:Retrospective Studies; D013030:Spain; D016896:Treatment Outcome; D000069470:Venlafaxine Hydrochloride; D055815:Young Adult
D018687:Antidepressive Agents, Second-Generation; D003511:Cyclohexanols; D004338:Drug Combinations; D015283:Citalopram; D000069470:Venlafaxine Hydrochloride